News | May 13, 2021
Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
The agreement will help ensure wider reach and access to patients in India
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
